A Phase 1 Study of MQ710 in People With Solid Tumors

Full Title

A First In Human Phase I, Open Label, Safety And Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, A Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination with The Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Purpose

In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.

MQ710 is a type of immunotherapy. It is made to kill tumor cells directly as well as boost your own immune system to fight cancer. It is injected directly into tumors.

Contact

For more information and to see if you can join this study, please contact Dr. Lara Dunn’s office at 646-608-3787.